OJNeph  Vol.3 No.2 , June 2013
Intensive Antihypertensive Treatment with Angiotensin Receptor Blocker Combined with Hydrocholorthiazide Reduces Urinary Angiotensinogen in Patients with Type 2 Diabetes Mellitus
Abstract: Purpose: Local activation of rennin-angiotensin system (RAS) is involved in the progression of chronic kidney disease (CKD). One of the RAS components, angiotensinogen (AGT) has been known to be a potential surrogate biomarker for the renal RAS activity. Measuring the daily urinary excretion of AGT (U-AGT), the present study addressed whether the intensive blood pressure (BP) lowering with combined antihypertensive agents could improve such an abnormality in diabetic CKD patients. Methods: Uncontrolled hypertensive patients with type 2 diabetes with mild to moderate nephropathy previously receiving angiotensin receptor blockers (ARB) in an optimal dose alone were recruited for a better blood pressure (BP) control. Urinary specimens were subjected to a quantitative measurement of a daily urinary protein (U-prot) and U-AGT. After the baseline measurement, intensive antihypertensive therapy was attempted by switching the ARB dose to a fixed combination formula of candesartan 8 mg plus hydrochlorthiazide (HCTZ) 6.25 mg and the patients were followed up for 24 weeks. Comparison of parameters was then made between the values at the baseline and the end of the study. Results: At baseline, there was a significant positive correlation between U-AGT and U-prot, and between U-AGT and serum creatinine (Cr) concentration. In addition, U-AGT was inversely correlated with estimated glomerular filtration rate (e-GFR). Switching the antihypertensive regime from ARB alone to the combined ARB/HCTZ significantly reduced BP, U-AGT and U-prot. The magnitude of the reduction in U-prot was positively correlated with that in U-AGT. A stepwise regression analysis showed that HbA1c, e-GFR and the reduction in U-prot in response to the intensive antihypertensive therapy were positively correlated with the reduction in U-AGT. Conclusion: U-AGT is increased and positively correlated with U-prot in patients with type 2 diabetic nephropathy. Intensive antihypertensive treatment with ARB combined with HCTZ reduces both U-AGT and U-prot, presumably via an amelioration of an accelerated renal RAS activity. These data also suggest that U-AGT can be used as a potential therapeutic surrogate biomarker for the activated renal RAS in patients with diabetic nephropathy.
Cite this paper: S. Kuriyama, N. Sugano, K. Takane, A. Kobayashi, Y. Otsuka and T. Hosoya, "Intensive Antihypertensive Treatment with Angiotensin Receptor Blocker Combined with Hydrocholorthiazide Reduces Urinary Angiotensinogen in Patients with Type 2 Diabetes Mellitus," Open Journal of Nephrology, Vol. 3 No. 2, 2013, pp. 89-96. doi: 10.4236/ojneph.2013.32015.

[1]   L. G. Navar, L. M. Harrison-Bernard, A. Nishiyama and H. Kobori, “Regulation of Intrarenal Angiotensin II in Hypertension,” Hypertension, Vol. 39, 2002, pp. 316-322. doi:10.1161/hy0202.103821

[2]   H. Kobori, M. Nangaku, L. G. Navar and A. Nishiyama, “The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease,” Pharmacological Reviews, Vol. 59, No. 3, 2007, pp. 251-287. doi:10.1124/pr.59.3.3

[3]   H. Kobori, Y. Ozawa, Y. Suzaki, M. C. Prieto-Carrasquero, A. Nishiyama, T. Shoji, E. P. Cohen and L. G. Navar, “Young Scholars Award Lecture: Intratubular Angiotensinogen in Hypertension and Kidney Diseases,” American Journal of Hypertension, Vol. 19, No. 5, 2006, pp. 541-550. doi:10.1016/j.amjhyper.2005.11.014

[4]   H. Kobori, Y. Ozawa, R. Satou, A. Katsurada, K. Miyata, N. Ohashi, N. Hase, Y. Suzaki, C. D. Sigmund and L. G. Navar, “Kidney-Specific Enhancement of ANG II Stimulates Endogenous Intrarenal Angiotensinogen in Genetargeted Mice,” American Journal of Physiology—Renal Physiology, Vol. 293, No. 3, 2007, pp. F938-F945. doi:10.1152/ajprenal.00146.2007

[5]   H. Kobori, L. M. Harrison-Bernard and L. G. Navar, “Urinary Excretion of Angiotensinogen Reflects Intrarenal Angiotensinogen Production,” Kidney International, Vol. 61, 2002, pp. 579-585. doi:10.1046/j.1523-1755.2002.00155.x

[6]   H. Kobori, A. Nishiyama, L. M. Harrison-Bernard and L. G. Navar, “Urinary Angiotensinogen as an Indicator of Intrarenal Angiotensin Status in Hypertension,” Hypertension, Vol. 41, 2003, pp. 42-49. doi:10.1161/01.HYP.0000050102.90932.CF

[7]   H. Kobori, A. B. Alper Jr., R. Shenava, A. Katsurada, T. Saito, N. Ohashi, M. Urushihara, K. Miyata, R. Satou, L. L. Hamm and L. G. Navar, “Urinary Angiotensinogen as a Novel Biomarker of the Intrarenal Renin-Angiotensin System Status in Hypertensive Patients,” Hypertension, Vol. 53, 2009, pp. 344-350. doi:10.1161/HYPERTENSIONAHA.108.123802

[8]   H. Kobori, Y. Ozawa, Y. Suzaki and A. Nishiyama, “Enhanced Intrarenal Angiotensinogen Contributes to Early Renal Injury in Spontaneously Hypertensive Rats,” Journal of the American Society of Nephrology, Vol. 16, No. 7, 2005, pp. 2073-2080. doi:10.1681/ASN.2004080676

[9]   T. Yamamoto, T. Nakagawa, H. Suzuki, N. Ohashi, H. Fukasawa, Y. Fujigaki, A. Kato, Y. Nakamura, F. Suzuki and A. Hishida, “Urinary Angiotensinogen as a Marker of Intrarenal Angiotensin II Activity Associated with Deterioration of Renal Function in Patients with Chronic Kidney Disease,” Journal of the American Society of Nephrology, Vol. 18, No. 5, 2007, pp. 1558-1565. doi:10.1681/ASN.2006060554

[10]   H. Kobori, A. Katsurada, Y. Ozawa, R. Satou, K. Miyata, N. Hase, Y. Suzaki and T. Shoji, “Enhanced Intrarenal Oxidative Stress and Angiotensinogen in IgA Nephropathy Patients,” Biochemical and Biophysical Research Communications, Vol. 358, No. 1, 2007, pp. 156-163. doi:10.1016/j.bbrc.2007.04.105

[11]   M. Takamatsu, M. Urushihara, S. Kondo, M. Shimizu, T. Morioka, T. Oite, H. Kobori and S. Kagami, “Glomerular Angiotensinogen Protein Is Enhanced in Pediatric IgA Nephropathy,” Pediatric Nephrology, Vol. 23, No. 8, 2008, pp. 1257-1267. doi:10.1007/s00467-008-0801-6

[12]   D. Russo, R. Minutolo, A. Pisani, R. Esposito, G. Signoriello, M. Andreucci and M. M. Balletta, “Coadministration of Losartan and Enalapril Exerts Additive Antiproteinuric Effect in IgA Nephropathy,” American Journal of Kidney Diseases, Vol. 38, No. 1, 2001, pp. 18-25. doi:10.1053/ajkd.2001.25176

[13]   K. F. Hilgers and J. F. Mann, “ACE Inhibitors versus AT(1) Receptor Antagonists in Patients with Chronic Renal Disease,” Journal of the American Society of Nephrology, Vol. 13, No. 4, 2002, pp. 1100-1108.

[14]   R. Coppo, L. Peruzzi, A. Amore, A. Piccoli, P. Cochat, R. Stone, M. Kirschstein and T. Linné, “IgACE: A Placebo-Controlled, Randomized Trial of AngiotensinConverting Enzyme Inhibitors in Children and Young People with IgA Nephropathy and Moderate Proteinuria,” Journal of the American Society of Nephrology, Vol. 18, No. 6, 2007, pp. 1880-1888. doi:10.1681/ASN.2006040347

[15]   G. L. Bakris, M. Williams, L. Dworkin, W. J. Elliott, M. Epstein, R. Toto, K. Tuttle, J. Douglas, W. Hsueh and J. Sower, “Preserving Renal Function on Adults with Hypertension ans Diabetes: A Consensus Approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group,” American Journal of Kidney Diseases, Vol. 36, No. 3, 2000, pp. 646-661. doi:10.1053/ajkd.2000.16225

[16]   B. Waeber, “Achieving Blood Pressure Targets in the Management of Hypertension,” Blood Pressure, Vol. 10, No. 2, 2001, pp. 6-12. doi:10.1080/080370501750275839-1

[17]   T. Hosoya, S. Kuriyama, I. Ohno, T. Kawamura, M. Ogura, M. Ikeda, M. Ishikawa, F. Hayashi, T. Kanai, H. Tomonari, M. Soejima, K. Akaba and G. Tokudome, “Antihypertensive Effect of a Fixed-Dose Combination of Losartan/Hydrochlorothiazide in Patients with Uncontrolled Hypertension: A Multicenter Study,” Clinical and Experimental Nephrology, Vol. 16, No. 2, 2012, pp. 269278. doi:10.1007/s10157-011-0564-4

[18]   American Diabetes Association, “Diagnosis and Classification of Diabetes Mellitus,” Diabetes Care, Vol. 35, Suppl. 1, 2012, pp. s64-s71. doi:10.2337/dc12-s064

[19]   T. Saito, M. Urushihara, Y. Kotani, S. Kagami and H. Kobori, “Increased Urinary Angiotensinogen Is Precedent to Increased Urinary Albumin in Patients with Type 1 Diasbetes,” The American Journal of the Medical Sciences, Vol. 338, 2009, pp. 478-480. doi:10.1097/MAJ.0b013e3181b90c25

[20]   S. Ogawa, H. Kobori, N. Ohashi, M. Urushihara, A. Nishiyama, T. Mori, T. Ishizuka, K. Nako and S. Ito, “Angiotensin II Type 1 Receptor Blockers Reduce Urinary Angiotensinogen Excretion and the Levels of Urinary Markers of Oxidative Stress and Inflammation in Patients with Type 2 Diabetic Nephropathy,” Biomark Insights, Vol. 4, 2009, pp. 97-102.

[21]   M. Sawaguchi, S. I. Araki, H. Kobori, M. Urushihara, M. Haneda, D. Koya, A. Kashiwagi, T. Uzu and H. Maegawa, “Association between Urinary Angiotensinogen Levels and Renal and Cardiovascular Prognoses in Patients with Type 2 Diabetes Mellitus,” Journal of Diabetes Investigation, Vol. 3, No. 3, 2012, pp. 318-324.

[22]   D. E. Casarini, “Upregulation of Intrarenal Angiotensinogen in Diabetes,” Hypertension Research, Vol. 33, 2010, pp. 1174-1181. doi:10.1038/hr.2010.163

[23]   A. Katsurada, Y. Hagiwara, K. Miyashita, R. Satou, K. Miyata, N. Ohashi, L. G. Navar and H. Kobori, “Novel Sandwich ELISA for Human Angiotensinogen,” American Journal of Physiology—Renal Physiology, Vol. 293, No. 3, 2007, pp. F956-F960. doi:10.1152/ajprenal.00090.2007

[24]   A. Nishiyama, Y. Konishi, N. Ohasi, T. Morikawa, M. Urushihara, I. Maeda, M. Hamada, M. Kishida, H. Hitomi, N. Shirahashi, H. Kobori and M. Imanishi, “Urinary Angiotensinogen Reflects the Activity of Intrarenal Renin Angiotensin System in Patients with IgA Nephropathy,” Nephrology Dialysis Transplantation, Vol. 26, No. 1, 2011, pp. 170-177. doi:10.1093/ndt/gfq371

[25]   H. R. Jang, S. M. Kim, Y. J. Lee, J. E. Lee, W. Huh, D. J. Kim, H. Y. Oh and Y. G. Kim, “The Origin and the Clinical Significance of Urinary Angiotensinogen in Proteinuric IgA Nephropathy Patients,” Annals of Internal Medicine, 2011.

[26]   Y. G. Kim, S. B. Song, S. H. Lee, J. Y. Moon, K. H. Jeong, T. W. Lee and C. G. Ihm, “Urinary Angiotensinogen as a Predictive Marker in Patients with Immunoglobulin A Nephropathy,” Clinical and Experimental Nephrology, Vol. 15, No. 5, 2011, pp. 720-726. doi:10.1007/s10157-011-0475-4

[27]   B. M. Brenner, M. E. Cooper, D. de Zeeuw, W. F. Keane, W. E. Mitch, H. H. Parving, G. Remuzzi, S. M. Snapinn, Z. Zhang and S. Shahinfar, “Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy,” New England Journal of Medicine, Vol. 345, 2001, pp. 861-869. doi:10.1056/NEJMoa011161

[28]   H. H. Parving, H. Lehnert, J. Bröchner-Mortensen, R. Gomis, S. Andersen and P. Arner, “Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes,” New England Journal of Medicine, Vol. 345, 2001, pp. 870878. doi:10.1056/NEJMoa011489

[29]   H. Makino, M. Haneda, T. Babazono, T. Moriya, S. Ito, Y. Iwamoto, R. Kawamori, M. Takeuchi and S. Katayama, “Prevention of Transition from Incipient to Overt Nephropathy with Telmisartan in Patients with Type 2 Diabetes,” Diabetes Care, Vol. 30, No. 6, 2007, pp. 1577-1578. doi:10.2337/dc06-1998

[30]   G. Viberti and N. M. Wheeldon, “MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Microalbuminuria Reduction with Valsartan in Patients with Type 2 Diabetes Mellitus: A Blood Pressure-Independent Effect,” Circulation, Vol. 106, 2002, pp. 672-678. doi:10.1161/01.CIR.0000024416.33113.0A

[31]   G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, S. Laurent, K. Narkiewicz, L. Ruilope, A. Rynkiewicz, R. E. Schmieder, H. A. Boudier, A. Zanchetti, A. Vahanian, J. Camm, R. De Caterina, V. Dean, K. Dickstein, G. Filippatos, C. Funck-Brentano, I. Hellemans, S. D. Kristensen, K. McGregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, J. L. Zamorano, S. Erdine, W. Kiowski, E. Agabiti-Rosei, E. Ambrosioni, L. H. Lindholm, M. Viigimaa, S. Adamopoulos, E. Agabiti-Rosei, E. Ambrosioni, V. Bertomeu, D. Clement, S. Erdine, C. Farsang, D. Gaita, G. Lip, J. M. Mallion, A. J. Manolis, P. M. Nilsson, E. O’Brien, P. Ponikowski, J. Redon, F. Ruschitzka, J. Tamargo, P. van Zwieten, B. Waeber and B. Williams, “Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC),” Journal of Hypertension, Vol. 25, 2007, pp. 1105-1187. doi:10.1097/HJH.0b013e3281fc975a

[32]   M. van den Heuvel, W. W. Batenburg, S. Jainandunsing, I. M. Garrelds, J. M. G. van Gool, R. A. Feelders, A. H. van den Meiracker and A. H. Jan Danser, “Urinary Renin, but Not Angiotensinogen or Aldosterone, Reflects the Renal Renin-Angiotensin-Aldosterone System Activity and the Efficacy of Renin-Angiotensin-Aldosterone System Blockade in the Kidney,” Journal of Hypertension, Vol. 29, 2011, pp. 2147-2155. doi:10.1097/HJH.0b013e32834bbcbf

[33]   T. Ogihara, K. Kikuchi, H. Matsuoka, T. Fujita, J. Higaki, M. Horiuchi, Y. Imai, T. Imaizumi, S. Ito, H. Iwao, K. Kario, Y. Kawano, S. Kim-Mitsuyama, G. Kimura, H. Matsubara, H. Matsuura, M. Naruse, I. Saito, K. Shimada, K. Shimamoto, H. Suzuki, S. Takishita, N. Tanahashi, T. Tsuchihashi, M. Uchiyama, S. Ueda, H. Ueshima, S. Umemura, T. Ishimitsu and H. Rakugi, “The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009),” Hypertension Research, Vol. 32, 2009, pp. 11-23. doi:10.1038/hr.2009.34

[34]   A. V. Chobanian, G. L. Bakris, H. R. Black, W. C. Cushman, L. A. Green, J. L. Izzo Jr., D. W. Jones, B. J. Materson, S. Oparil, J. T. Wright Jr. and E. J. Roccella, “National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,” JAMA, Vol. 289, No. 19, 2003, pp. 2560-2572. doi:10.1001/jama.289.19.2560